Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Authors
Banerjee, SOza, A
Birrer, M
Hamilton, E
Hasan, Jurjees
Leary, A
Moore, K
Mackowiak-Matejczyk, B
Pikiel, J
Ray-Coquard, I
Trask, P
Lin, K
Schuth, E
Vaze, A
Choi, Y
Marsters, J
Maslyar, D
Lemahieu, V
Wang, Y
Humke, E
Liu, J
Affiliation
Royal Marsden NHS Foundation Trust and Institute of Cancer Research, LondonIssue Date
2018-02-01
Metadata
Show full item recordAbstract
Lifastuzumab vedotin (LIFA) is a humanized anti-NaPi2b monoclonal antibody conjugated to a potent anti-mitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. This study is the first to compare an antibody-drug-conjugate (ADC) to standard-of-care in ovarian cancer (OC) patients.Citation
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. 2018, Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdy023PubMed ID
29401246Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy023
Scopus Count
Collections
Related articles
- Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
- Authors: Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P
- Issue date: 2012 Nov 1
- Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.
- Authors: Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG
- Issue date: 2010 Jul
- Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
- Authors: Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, Lemahieu V, Armstrong K, Cordova J, Samineni D, Schuth E, Vaze A, Maslyar D, Humke EW, Hamilton EP, Liu JF
- Issue date: 2020 Sep
- Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
- Authors: Lawrie TA, Bryant A, Cameron A, Gray E, Morrison J
- Issue date: 2013 Jul 9
- Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
- Authors: McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R Jr
- Issue date: 2018 Dec 27